---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-001681"
form_type: "8-K"
ticker: "SRRK"
cik: "0001727196"
company_name: "Scholar Rock Holding Corp"
filed_at: "2025-02-27T23:59:59+00:00"
generated_at: "2026-05-26T02:17:08.770068+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Scholar Rock reports FY 2024 net loss of $2.47/share; BLA submitted for apitegromab in SMA

## Summary
- Net loss $246.3M ( $2.47 /share) vs $165.8M ( $1.99 /share) in FY 2023; zero revenue.
- Cash, equivalents & marketable securities $437.3M; expanded credit facility adds up to $150M in tranches.
- BLA for apitegromab in SMA submitted Jan 2025; US launch planned 4Q 2025; EU MAA expected 1Q 2025.
- Phase 2 EMBRAZE topline data (apitegromab+tirzepatide in obesity) expected 2Q 2025; IND for SRK-439 in 3Q 2025.
- COO/CFO Ted Myles departing; search for new CFO; Lisa Wyman appointed CTQO.

## SEC filing metadata
- accession: 0001558370-25-001681
- form_type: 8-K
- ticker: SRRK
- cik: 0001727196
- company_name: Scholar Rock Holding Corp
- filed_at: 2025-02-27T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1727196/000155837025001681/0001558370-25-001681-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1727196/000155837025001681/srrk-20250227x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-001681
- JSON: https://secwatch.observer/filing/0001558370-25-001681.json
- Plain text: https://secwatch.observer/filing/0001558370-25-001681.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.